Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 51

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 51
---
 connection with Kadimastem’s development program and from general and administrative costs associated with Kadimastem’s
operations.

Until Kadimastem can generate significant revenues, if ever, it expects to satisfy Kadimastem’s future cash needs through debt or equity financing. It cannot be certain that additional funding will be available to it on acceptable terms, if at all. If funds are not available, Kadimastem may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to Kadimastem’s products.

Kadimastem expects its research
and development expenses to increase in connection with its planned expanded clinical trials. In addition, if Kadimastem obtains marketing
approval for AstroRx and/or IsletRx or any other current or future product candidate, it will likely incur significant sales, marketing
and outsourced manufacturing expenses, as well as continued research and development expenses. Furthermore, in the period following this
prospectus, it expects to incur additional costs associated with operating as a public company, which Kadimastem estimates will be at
least several hundred thousand dollars annually. As a result, Kadimastem expects to continue to incur significant and increasing operating
losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products,
Kadimastem is unable to predict the extent of any future losses or when it will become profitable, if at all.

Furthermore, in addition
to such operating expenses, Kadimastem expects to incur additional costs associated with operating as a public company subject to the
rules and regulations of the SEC, which it estimates will be at least one million dollars annually. As a result, Kadimastem expects to
continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties
associated with developing drug substances and product candidates, Kadimastem is unable to predict the extent of any future losses or
when Kadimastem will become profitable, if at all.

<div align='center'>39</div>

Kadimastem expects to continue
to incur significant losses until Kadimastem are able to commercialize Kadimastem’s product candidates, which it may not be successful
in achieving. Kadimastem anticipate that Kadimastem’s expenses will increase substantially if and as we:

| ● | continue the research and development of Kadimastem’s product candidates;             |
| ●